Preclinical Characterization of Pan-NKG2D Ligand-binding NKG2D Receptor Decoys

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Apr 8

PMID 38586421

Authors

Peter B Rupert

Matthew Buerger

Emily J Girard

Marie Frutoso

Don Parrilla

Kevin Ng

Theodore Gooley

Veronika Groh

Roland K Strong

Affiliations

Soon will be listed here.

Abstract

NKG2D and its ligands are critical regulators of protective immune responses controlling infections and cancer, defining a crucial immune signaling axis. Current therapeutic efforts targeting this axis almost exclusively aim at enhancing NKG2D-mediated effector functions. However, this axis can drive disease processes when dysregulated, in particular, driving stem-like cancer cell reprogramming and tumorigenesis through receptor/ligand self-stimulation on tumor cells. Despite complexities with its structure and biology, we developed multiple novel engineered proteins that functionally serve as axis-blocking NKG2D "decoys" and report biochemical, structural, , and evaluation of their functionality.

References

Jaberi S, Cohen A, DSouza C, Abdulrazzaq Y, Ojha S, Bastaki S . Lipocalin-2: Structure, function, distribution and role in metabolic disorders. Biomed Pharmacother. 2021; 142:112002. DOI: 10.1016/j.biopha.2021.112002. View

Garrity D, Call M, Feng J, Wucherpfennig K . The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci U S A. 2005; 102(21):7641-6. PMC: 1140444. DOI: 10.1073/pnas.0502439102. View

Risti M, da Graca Bicalho M . MICA and NKG2D: Is There an Impact on Kidney Transplant Outcome?. Front Immunol. 2017; 8:179. PMC: 5326783. DOI: 10.3389/fimmu.2017.00179. View

Zuo J, Willcox C, Mohammed F, Davey M, Hunter S, Khan K . A disease-linked polymorphism inhibits NKG2D-mediated target cell killing by enhancing the stability of NKG2D ligand binding. Sci Signal. 2017; 10(481). DOI: 10.1126/scisignal.aai8904. View

Hou Y, Hu S, Li X, He W, Wu G . Amino Acid Metabolism in the Liver: Nutritional and Physiological Significance. Adv Exp Med Biol. 2020; 1265:21-37. DOI: 10.1007/978-3-030-45328-2_2. View

Radaev S, Rostro B, Brooks A, Colonna M, Sun P . Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like ligand ULBP3. Immunity. 2002; 15(6):1039-49. DOI: 10.1016/s1074-7613(01)00241-2. View

Winn M, Isupov M, Murshudov G . Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr D Biol Crystallogr. 2001; 57(Pt 1):122-33. DOI: 10.1107/s0907444900014736. View

Cai X, Caballero-Benitez A, Gewe M, Jenkins I, Drescher C, Strong R . Control of Tumor Initiation by NKG2D Naturally Expressed on Ovarian Cancer Cells. Neoplasia. 2017; 19(6):471-482. PMC: 5429243. DOI: 10.1016/j.neo.2017.03.005. View

Allez M, Skolnick B, Wisniewska-Jarosinska M, Petryka R, Overgaard R . Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn's disease: a randomised controlled trial. Gut. 2016; 66(11):1918-1925. DOI: 10.1136/gutjnl-2016-311824. View

10.

Dekkers G, Bentlage A, Stegmann T, Howie H, Lissenberg-Thunnissen S, Zimring J . Affinity of human IgG subclasses to mouse Fc gamma receptors. MAbs. 2017; 9(5):767-773. PMC: 5524164. DOI: 10.1080/19420862.2017.1323159. View

11.

Crook Z, Girard E, Sevilla G, Merrill M, Friend D, Rupert P . A TfR-Binding Cystine-Dense Peptide Promotes Blood-Brain Barrier Penetration of Bioactive Molecules. J Mol Biol. 2020; 432(14):3989-4009. PMC: 9569163. DOI: 10.1016/j.jmb.2020.04.002. View

12.

Babic M, Romagnani C . The Role of Natural Killer Group 2, Member D in Chronic Inflammation and Autoimmunity. Front Immunol. 2018; 9:1219. PMC: 5992374. DOI: 10.3389/fimmu.2018.01219. View

13.

Vagin A, Teplyakov A . Molecular replacement with MOLREP. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 1):22-5. DOI: 10.1107/S0907444909042589. View

14.

Gomez-Cadena A, Spehner L, Kroemer M, Ben Khelil M, Bouiller K, Verdeil G . Severe COVID-19 patients exhibit an ILC2 NKG2D population in their impaired ILC compartment. Cell Mol Immunol. 2020; 18(2):484-486. PMC: 7734385. DOI: 10.1038/s41423-020-00596-2. View

15.

Chang V, Crispin M, Aricescu A, Harvey D, Nettleship J, Fennelly J . Glycoprotein structural genomics: solving the glycosylation problem. Structure. 2007; 15(3):267-73. PMC: 1885966. DOI: 10.1016/j.str.2007.01.011. View

16.

. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr. 1994; 50(Pt 5):760-3. DOI: 10.1107/S0907444994003112. View

17.

Wu J, Song Y, Bakker A, Bauer S, Spies T, Lanier L . An activating immunoreceptor complex formed by NKG2D and DAP10. Science. 1999; 285(5428):730-2. DOI: 10.1126/science.285.5428.730. View

18.

Winn M, Ballard C, Cowtan K, Dodson E, Emsley P, Evans P . Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr. 2011; 67(Pt 4):235-42. PMC: 3069738. DOI: 10.1107/S0907444910045749. View

19.

Eagle R, Trowsdale J . Promiscuity and the single receptor: NKG2D. Nat Rev Immunol. 2007; 7(9):737-44. DOI: 10.1038/nri2144. View

20.

Benitez A, Dai Z, Mann H, Reeves R, Margineantu D, Gooley T . Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells. Proc Natl Acad Sci U S A. 2011; 108(10):4081-6. PMC: 3054013. DOI: 10.1073/pnas.1018603108. View